MAP2K7 and acral lentiginous melanoma: Altogether, these findings represent the seminal report of an intrinsic and acquired CDK4i/6i resistance mechanism in ALM and conclude the addition of a MEK inhibitor may increase the durability of first- and second-line CDK4i/6i therapy in patients with advanced ALM.